loading page

Outcomes of Pediatric Hodgkin Lymphoma; A retrospective review of children and adolescents with Hodgkin lymphoma treated at King Fahad Medical City, Riyadh, 2006-2017
  • Amal Daghriri,
  • Bilal AlBtoosh
Amal Daghriri
King Fahad Medical City

Corresponding Author:[email protected]

Author Profile
king fahad medical city
Author Profile
Bilal AlBtoosh
King Fahad Medical City
Author Profile


Background: Treatment outcomes for children and adolescents with Hodgkin lymphoma (HL) have improved over the past few decades. Most patients achieve long-term remission with a five-year survival of approximately 90%, as reported by different treatment groups in developed countries. However, there are limited data on the outcome of patients treated in developing countries. Here we report the outcomes of children and adolescents treated at a comprehensive cancer center in Riyadh, Saudi Arabia. Procedure: A retrospective review of the medical records of all pediatric patients younger than 16 years who were diagnosed with HL from July 2006 through December 2017 was performed. Results: Of the 54 patients with HL, 70.37% were boys with a median age of 9 years (mean ± SD, 9.11 ± 3.30). A total of 51.85% had B symptoms and 33.33% had bulky disease. The nodular sclerosis type was the most common histological subtype (48.15%). In total, 74.07% of the patients presented with advanced stage III and IV disease. The three-years relapse-free survival rate was approximately 82%, and the three overall survival (OS) rate was more than 95%. Conclusions: Survival outcomes in children and adolescents with HL in Saudi Arabia have improved with a five‐year OS rate now exceeding 85%. However, further prospective larger collaborative studies are necessary.